Enterprise Value

44.3M

Cash

127.5M

Avg Qtr Burn

-40.1M

Short % of Float

25.71%

Insider Ownership

31.03%

Institutional Own.

60.64%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BXCL501 Details
Bipolar depression, Bipolar disease, Mental health, Schizophrenia

Approved

Quarterly sales

BXCL501 Details
Dementia, Alzheimer's disease, Agitation in Alzheimer's Disease

sNDA

Submission

BXCL501 Details
Bipolar depression, Bipolar disease, Mental health, Schizophrenia

Phase 3

Update

BXCL701 + KEYTRUDA Details
Neuroendocrine prostate cancer, Castration-resistant prostate cancer

Phase 2b

Initiation

BXCL701 + KEYTRUDA Details
Solid tumor/s, Pancreatic cancer, Cancer

Phase 2

Data readout

BXCL501 + Duloxetine Details
Major depressive disorder

Phase 2

Initiation

BXCL501 Details
Mental health, Delirium, Agitation

Failed

Discontinued

BXCL501 Details
Opioid use disorder

Failed

Discontinued